DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Prosthetic Joint Infections - Pipeline Review, H1 2017" report to their offering.
Prosthetic joint infections - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Prosthetic joint infections (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Prosthetic joint infections (Musculoskeletal Disorders) pipeline guide also reviews key players involved in therapeutic development for Prosthetic joint infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Preclinical, Discovery and Unknown stages are 1, 4, 1 and 1 respectively.
Prosthetic joint infections (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Key Topics Covered:
- Prosthetic joint infections - Overview
- Prosthetic joint infections - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Products under Development by Companies
- Prosthetic joint infections - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Prosthetic joint infections - Companies Involved in Therapeutics Development
- Cempra Inc
- Motif Bio Plc
- Nabriva Therapeutics AG
- Telephus Medical LLC
- TenNor Therapeutics Ltd
For more information about this report visit https://www.researchandmarkets.com/research/hd2ztz/prosthetic_joint